Vertex Pharmaceuticals, Inc. (VRTX)

Schlusskurs vom Vortag:

$392.81

Offen:

$392.81

24-Stunden-Volumen:

1.24M

Marktkapitalisierung:

$103.94B

Einnahmen:

$9.87B

Nettoeinkommen (Verlust:

$3.62B

KGV:

30.17

EPS:

13.33

Netto-Cashflow:

$3.28B

1W Leistung:

+0.34%

1M Leistung:

-4.36%

6M Leistung:

+8.88%

1J Leistung:

+16.56%

1-Tages-Spanne:

$392.47

$406.95

52-Wochen-Spanne:

$320.01

$448.40

Vertex Pharmaceuticals, Inc. Stock (VRTX) Company Profile

Firmenname

Vertex Pharmaceuticals, Inc.

Sektor

Healthcare (1189)

Branche

Biotechnology (685)

Telefon

617-341-6100

Adresse

50 Northern Avenue, Boston, MA

Mitarbeiter

2,300

Twitter

@VertexPharma

Nächster Verdiensttermin

2024-05-15

Neueste SEC-Einreichungen

VRTX's Discussions on Twitter

Vertex Pharmaceuticals, Inc. Stock (VRTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2024-02-06	Herabstufung	Evercore ISI	Outperform → In-line
2024-02-02	Herabstufung	Bernstein	Outperform → Mkt Perform
2024-01-31	Herabstufung	Maxim Group	Buy → Hold
2024-01-31	Herabstufung	Robert W. Baird	Neutral → Underperform
2024-01-24	Herabstufung	Canaccord Genuity	Hold → Sell
2023-12-14	Bestätigt	RBC Capital Mkts	Sector Perform
2023-05-30	Eingeleitet	William Blair	Outperform
2023-05-04	Fortgesetzt	Piper Sandler	Overweight
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-01-18	Eingeleitet	Canaccord Genuity	Hold
2023-01-17	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-12-19	Herabstufung	Jefferies	Buy → Hold
2022-07-13	Eingeleitet	Cantor Fitzgerald	Overweight
2022-06-01	Hochstufung	Maxim Group	Hold → Buy
2022-05-23	Eingeleitet	SVB Leerink	Mkt Perform
2022-05-06	Herabstufung	Robert W. Baird	Outperform → Neutral
2022-05-03	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-02-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-01-27	Bestätigt	JP Morgan	Overweight
2022-01-27	Bestätigt	Morgan Stanley	Underweight
2022-01-27	Bestätigt	RBC Capital Mkts	Outperform
2022-01-27	Bestätigt	Stifel	Hold
2022-01-27	Bestätigt	Wolfe Research	Outperform
2022-01-20	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-12-09	Eingeleitet	Wells Fargo	Overweight
2021-11-19	Eingeleitet	BMO Capital Markets	Market Perform
2021-11-19	Herabstufung	Piper Sandler	Overweight → Neutral
2021-09-09	Herabstufung	Stifel	Buy → Hold
2021-09-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-07-20	Herabstufung	SVB Leerink	Mkt Perform → Underperform
2021-07-19	Fortgesetzt	Wolfe Research	Outperform
2021-07-01	Eingeleitet	Raymond James	Mkt Perform
2021-06-11	Herabstufung	Daiwa Securities	Outperform → Neutral
2021-02-23	Hochstufung	Robert W. Baird	Neutral → Outperform
2021-02-02	Bestätigt	H.C. Wainwright	Buy
2020-12-30	Eingeleitet	Daiwa Securities	Outperform
2020-11-30	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2020-11-20	Eingeleitet	Bernstein	Outperform
2020-10-28	Eingeleitet	UBS	Buy
2020-07-31	Bestätigt	H.C. Wainwright	Buy
2020-07-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-04-30	Bestätigt	H.C. Wainwright	Buy
2020-04-28	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-31	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-11-19	Hochstufung	Guggenheim	Neutral → Buy
2019-11-12	Eingeleitet	SunTrust	Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Buy
2019-09-03	Hochstufung	Goldman	Neutral → Buy
2019-08-01	Herabstufung	Needham	Buy → Hold
2019-05-23	Fortgesetzt	Citigroup	Buy
2019-05-21	Eingeleitet	Credit Suisse	Outperform
2019-04-12	Eingeleitet	Evercore ISI	In-line
2019-03-26	Hochstufung	William Blair	Mkt Perform → Outperform
2019-03-19	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-02-06	Herabstufung	Maxim Group	Buy → Hold

Alle ansehen

Vertex Pharmaceuticals, Inc. Aktie (VRTX) Neueste Nachrichten

Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know

Zacks Investment Research

Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics

Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

2 Top Growth Stocks to Buy Right Now and Hold Forever

The Motley Fool

Finanzdaten der Vertex Pharmaceuticals, Inc.-Aktie (VRTX)

Vertex Pharmaceuticals, Inc. (VRTX) Umsatz 2024

Vertex Pharmaceuticals, Inc. (VRTX) Nettogewinn 2024

Vertex Pharmaceuticals, Inc. (VRTX) Free Cashflow 2024

Vertex Pharmaceuticals, Inc. (VRTX) Gewinn je Aktie 2024

Vertex Pharmaceuticals, Inc.-Aktie (VRTX) Insiderhandel